author-photo

Daniel Yick Chin Heng

University of Calgary
Tom Baker Cancer Centre

203

Papers

1540

Citations

Citation Trend

Filter By

Papers (134) Sort By

Journal Conference Others

Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)

2021
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.

2021
Show All
- Source
- Cite
- Save
Citations (10)
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

2021 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (0)
The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

2021 The Lancet
Show All
- Source
- Cite
- Save
Citations (31)